echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > J Allergy Clin Immunol: Study Reveals Molecular Mechanism of Spesolimab in the Treatment of Pustular Psoriasis

    J Allergy Clin Immunol: Study Reveals Molecular Mechanism of Spesolimab in the Treatment of Pustular Psoriasis

    • Last Update: 2022-05-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The IL-36 pathway plays a key role in the pathogenesis of generalized pustular psoriasis (GPP)


    Investigators collected pre- and post-treatment skin and blood samples from GPP patients enrolled in a single-arm phase I study (n = 7)


    immunity

     

    As a result, 1287 transcripts were up- or down-regulated in GPP and PPP lesions


    Taken together, our findings suggest that in GPP patients, spesolimab intervention rapidly modulates dysregulated molecular pathways commonly seen in GPP and PPP patients, which may be related to its ability to improve clinical outcomes in these patients


     

    Original source:

     

    Patrick Baum, et al.


    Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasisLeave

    a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.